MSLN and pancreatic neoplasm: Therefore, the combination of nivolumab with GVAX (allogeneic pancreatic tumor cells secreting granulocyte–macrophage colony-stimulating factor) and CRS-207 (attenuated Listeria monocytogenes expressing mesothelin) was used to enhance the antitumor immune response to PDAC; however, the RR was only 2% [18].